TPST
Price:
$1.24
Market Cap:
$31.26M
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.[Read more]
Industry
Biotechnology
IPO Date
2012-11-12
Stock Exchange
NASDAQ
Ticker
TPST
According to Tempest Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.77. This represents a change of -63.36% compared to the average of -2.10 of the last 4 quarters.
The mean historical PE Ratio of Tempest Therapeutics, Inc. over the last ten years is -3.04. The current -0.77 PE Ratio has changed 2.44% with respect to the historical average. Over the past ten years (40 quarters), TPST's PE Ratio was at its highest in in the September 2023 quarter at -0.16. The PE Ratio was at its lowest in in the December 2014 quarter at -15.92.
Average
-3.04
Median
-0.64
Minimum
-20.22
Maximum
-0.00
Discovering the peaks and valleys of Tempest Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 10.30%
Maximum Annual PE Ratio = -0.00
Minimum Annual Increase = -99.27%
Minimum Annual PE Ratio = -20.22
Year | PE Ratio | Change |
---|---|---|
2023 | -2.30 | 536.93% |
2022 | -0.36 | -46.68% |
2021 | -0.68 | 1.19% |
2020 | -0.05 | -97.47% |
2019 | -2.07 | 358.29% |
2018 | -0.45 | 10.30% |
2017 | -0.00 | -99.27% |
2016 | -0.60 | -83.46% |
2015 | -3.61 | -82.13% |
2014 | -20.22 | 183.76% |
The current PE Ratio of Tempest Therapeutics, Inc. (TPST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.11
5-year avg
-1.09
10-year avg
-3.04
Tempest Therapeutics, Inc.’s PE Ratio is greater than Indaptus Therapeutics, Inc. (-0.78), greater than Rezolute, Inc. (-3.80), less than Comera Life Sciences Holdings, Inc. (-0.01), less than Forte Biosciences, Inc. (-0.39), greater than Sana Biotechnology, Inc. (-4.82), greater than Olema Pharmaceuticals, Inc. (-6.07), greater than Cullinan Oncology, Inc. (-6.96), greater than aTyr Pharma, Inc. (-2.33), greater than Zentalis Pharmaceuticals, Inc. (-1.08), greater than Lyell Immunopharma, Inc. (-1.42), greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Revolution Medicines, Inc. (-13.31), greater than ZIVO Bioscience, Inc. (-2.46), greater than RenovoRx, Inc. (-3.02), greater than Ikena Oncology, Inc. (-1.22), less than Catalyst Biosciences, Inc. (-0.44), greater than Akari Therapeutics, Plc (-1.55), greater than Armata Pharmaceuticals, Inc. (-1.26), greater than Anebulo Pharmaceuticals, Inc. (-4.99), less than Scopus BioPharma Inc. (-0.00), less than Processa Pharmaceuticals, Inc. (-0.37),
Company | PE Ratio | Market cap |
---|---|---|
-0.78 | $14.58M | |
-3.80 | $240.80M | |
-0.01 | $682.38K | |
-0.39 | $11.11M | |
-4.82 | $1.12B | |
-6.07 | $677.46M | |
-6.96 | $1.04B | |
-2.33 | $131.12M | |
-1.08 | $210.48M | |
-1.42 | $299.52M | |
-3.11 | $349.21M | |
-3.19 | $181.50M | |
-13.31 | $6.99B | |
-2.46 | $37.03M | |
-3.02 | $24.47M | |
-1.22 | $81.56M | |
-0.44 | $19.42M | |
-1.55 | $35.02M | |
-1.26 | $84.31M | |
-4.99 | $46.68M | |
-0.00 | $12.63K | |
-0.37 | $4.17M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tempest Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Tempest Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Tempest Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Tempest Therapeutics, Inc. (TPST)?
What is the highest PE Ratio for Tempest Therapeutics, Inc. (TPST)?
What is the 3-year average PE Ratio for Tempest Therapeutics, Inc. (TPST)?
What is the 5-year average PE Ratio for Tempest Therapeutics, Inc. (TPST)?
How does the current PE Ratio for Tempest Therapeutics, Inc. (TPST) compare to its historical average?